Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Folliculin is a highly conserved multifunctional protein with a key role in tumor suppression and homeostatic signaling, forming complexes with FNIP1 and FNIP2 and modulating AMPK and mTORC1 pathways. Loss-of-function mutations in FLCN cause autosomal dominant Birt-Hogg-Dubé syndrome, leading to renal neoplasia, skin papules (fibrofolliculomas), and pulmonary cysts. Structural studies show folliculin sharing features with DENN domain proteins, functioning as a GAP for Rag GTPases, thereby regulating lysosomal recruitment of mTORC1, autophagy, and transcription factors (TFEB/TFE3). Additional roles are described in cytoskeletal dynamics, cell adhesion, cell cycle control, and mitochondrial biogenesis. Interruption of folliculin activity drives cellular dysregulation and tumor predisposition, but no targeted therapies or direct inhibitors of FLCN are currently in clinical use.
Drugs that modulate mTORC1 (e.g., mTOR inhibitors like rapamycin) may functionally intersect with FLCN downstream effects. No direct FLCN-targeting mechanisms currently established for approved therapies.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Folliculin (FLCN).